The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Subscribe To Our Newsletter & Stay Updated
